0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Gut Microbiota−Tryptophan Metabolism−GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sodium–glucose cotransporter 2 inhibitors, efficacious antidiabetic agents that have cardiovascular and renal benefits, can promote pancreatic β-cell regeneration in type 2 diabetic mice. However, the underlying mechanism remains unclear. In this study, we aimed to use multiomics to identify the mediators involved in β-cell regeneration induced by dapagliflozin. We showed that dapagliflozin lowered blood glucose level, upregulated plasma insulin level, and increased islet area in db/db mice. Dapagliflozin reshaped gut microbiota and modulated microbiotic and plasmatic metabolites related to tryptophan metabolism, especially l-tryptophan, in the diabetic mice. Notably, l-tryptophan upregulated the mRNA level of glucagon-like peptide 1 (GLP-1) production–related gene ( Gcg and Pcsk1) expression and promoted GLP-1 secretion in cultured mouse intestinal L cells, and it increased the supernatant insulin level in primary human islets, which was eliminated by GPR142 antagonist. Transplant of fecal microbiota from dapagliflozin-treated mice, supplementation of l-tryptophan, or treatment with dapagliflozin upregulated l-tryptophan, GLP-1, and insulin or C-peptide levels and promoted β-cell regeneration in db/db mice. Addition of exendin 9-39, a GLP-1 receptor (GLP-1R) antagonist, or pancreatic Glp1r knockout diminished these beneficial effects. In summary, treatment with dapagliflozin in type 2 diabetic mice promotes β-cell regeneration by upregulating GLP-1 production, which is mediated via gut microbiota and tryptophan metabolism.

          Article Highlights
          • Sodium–glucose cotransporter 2 inhibitors, novel and efficacious antidiabetic agents, can preserve β-cell mass in type 2 diabetic animals, but the mechanism remains unclear.

          • We find that dapagliflozin reshapes gut microbiota, improves microbiotic and plasmatic metabolites related to tryptophan metabolism, and increases glucagon-like peptide 1 (GLP-1) production mediated via tryptophan metabolism. GLP-1−GLP-1 receptor signaling participates in the dapagliflozin-induced β-cell regeneration.

          • Our study reveals that the gut microbiota–tryptophan metabolism–GLP-1 axis is a novel mechanism of β-cell regeneration induced by dapagliflozin and provides experimental evidence for its β-cell protection in treating type 2 diabetes.

          Graphical Abstract

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

          The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

            Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A metagenome-wide association study of gut microbiota in type 2 diabetes.

              Assessment and characterization of gut microbiota has become a major research area in human disease, including type 2 diabetes, the most prevalent endocrine disease worldwide. To carry out analysis on gut microbial content in patients with type 2 diabetes, we developed a protocol for a metagenome-wide association study (MGWAS) and undertook a two-stage MGWAS based on deep shotgun sequencing of the gut microbial DNA from 345 Chinese individuals. We identified and validated approximately 60,000 type-2-diabetes-associated markers and established the concept of a metagenomic linkage group, enabling taxonomic species-level analyses. MGWAS analysis showed that patients with type 2 diabetes were characterized by a moderate degree of gut microbial dysbiosis, a decrease in the abundance of some universal butyrate-producing bacteria and an increase in various opportunistic pathogens, as well as an enrichment of other microbial functions conferring sulphate reduction and oxidative stress resistance. An analysis of 23 additional individuals demonstrated that these gut microbial markers might be useful for classifying type 2 diabetes.
                Bookmark

                Author and article information

                Journal
                Diabetes
                Diabetes
                diabetes
                Diabetes
                American Diabetes Association
                0012-1797
                1939-327X
                June 2024
                12 March 2024
                12 March 2024
                : 73
                : 6
                : 926-940
                Affiliations
                [1 ]Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, China
                [2 ]Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China
                [3 ]Department of Urology, Peking University Third Hospital, Beijing, China
                [4 ]Center for Reproductive Medicine, Peking University Third Hospital, Beijing, China
                [5 ]Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
                Author notes

                Y.J., J.Y., and L.X. contributed equally to this work.

                Corresponding authors: Zhe Zhang, zhezhang@ 123456bjmu.edu.cn ; Tianpei Hong, tpho66@ 123456bjmu.edu.cn ; and Rui Wei, weirui@ 123456bjmu.edu.cn
                Author information
                https://orcid.org/0000-0002-5744-5129
                https://orcid.org/0000-0002-8838-703X
                Article
                230553
                10.2337/db23-0553
                11109800
                38471012
                d3eb206c-1080-46cf-90c6-ca9a0ace580d
                © 2024 by the American Diabetes Association

                Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.

                History
                : 13 July 2023
                : 26 February 2024
                Funding
                Funded by: Talent Project of Clinical Key Project of Peking University Third Hospital;
                Funded by: National Natural Science Foundation of China, DOI 10.13039/501100001809;
                Award ID: 82070319
                Award ID: 82100885
                Award ID: 82170875
                Award ID: 82200908
                Award ID: 82270843
                Award ID: 82271611
                Funded by: the National Clinical Key Specialty Construction Program, P. R. China (2023);
                Funded by: Clinical Medicine Plus X-Young Scholars Project of Peking University;
                Award ID: PKU2023LCXQ025
                Funded by: Beijing Municipal Natural Science Foundation, DOI 10.13039/501100005089;
                Award ID: 7222216
                Award ID: 7232198
                Funded by: Tianjin Municipal Human Resources and Social Security Bureau, DOI 10.13039/501100011500;
                Award ID: XB202011
                This work was supported by National Clinical Key Specialty Construction Program, P.R. China (2023) special funding; National Natural Science Foundation of China grants 82270843, 82170875, 82371588, 82100885, 82200908, and 82271611; Beijing Municipal Natural Science Foundation grants 7232198 and 7222216; Clinical Medicine Plus X-Young Scholars Project of Peking University grant PKU2023LCXQ025; the Talent Project of Clinical Key Project of Peking University Third Hospital; and Tianjin Municipal Human Resources and Social Security Bureau grant XB202011.
                Categories
                Islet Studies

                Endocrinology & Diabetes
                Endocrinology & Diabetes

                Comments

                Comment on this article